Moolec Science (MLECW) Short term Debt (2022 - 2025)
Moolec Science (MLECW) posted Short term Debt of $227.2 million for Q2 2025, up 1072.59% sequentially from $19.4 million in Q4 2024, and down 3.14% YoY from $234.5 million in Q2 2024.
Moolec Science (MLECW) Short term Debt (2022 - 2025) Analysis & Trends
Moolec Science has reported Short term Debt for 4 years, with the latest figure at $227.2 million in Q2 2025.
- Quarterly Short term Debt fell 3.14% year-over-year to $227.2 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $227.2 million (down 3.14% YoY) and the FY2025 annual result came in at $227.2 million, down 3.14% from the prior year.
- Short term Debt rose to $227.2 million in Q2 2025 per MLECW's latest filing, from $19.4 million in the prior quarter.
- Over five years, Short term Debt peaked at $234.5 million in Q2 2024 and troughed at $1171.0 in Q2 2022.
- A 4-year average of $48.4 million and a median of $10.6 million in 2024 frame the typical range for Short term Debt.
- The sharpest annual moves came in 2023 and 2025: Short term Debt surged 1023457.64% in 2023, then declined 3.14% in 2025.
- Over 4 years, Short term Debt stood at $838117.0 in 2022, then surged by 570.3% to $5.6 million in 2023, then surged by 244.83% to $19.4 million in 2024, then jumped by 1072.59% to $227.2 million in 2025.
- According to Business Quant data, Short term Debt over the past three periods registered $227.2 million, $19.4 million, and $18.2 million for Q2 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 227.15 Mn |
| Dec 31, 2024 | 19.37 Mn |
| Sep 30, 2024 | 18.22 Mn |
| Jun 30, 2024 | 234.51 Mn |
| Mar 31, 2024 | 10.61 Mn |
| Dec 31, 2023 | 5.62 Mn |
| Sep 30, 2023 | 2.39 Mn |
| Jun 30, 2023 | 11.99 Mn |
| Mar 31, 2023 | 1.18 Mn |
| Dec 31, 2022 | 838,117.00 |
| Jun 30, 2022 | 1,171.00 |